ScholarIQanswers from OpenAlex

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

PaperCitations, authors & open-access status

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer have?

ScholarIQcitation count

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer has 114 citations in the OpenAlex counts ScholarIQ stores.

When was The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer published?

ScholarIQyear

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer has 2021 year in the ScholarIQ index.

What is the open-access status of The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer?

ScholarIQoa status

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer has gold oa status in the ScholarIQ index.

What is the DOI of The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer?

ScholarIQdoi

The DOI for The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer is on the source record.

What is the PMID of The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer?

ScholarIQpmid

The PMID for The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer is on the source record.

What is the OpenAlex record for The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer?

ScholarIQopenalex

The OpenAlex for The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial